Generic Cosela Availability
Last updated on May 9, 2024.
Cosela is a brand name of trilaciclib, approved by the FDA in the following formulation(s):
COSELA (trilaciclib dihydrochloride - powder;intravenous)
-
Manufacturer: G1 THERAP
Approval date: February 12, 2021
Strength(s): EQ 300MG BASE/VIAL [RLD]
Has a generic version of Cosela been approved?
No. There is currently no therapeutically equivalent version of Cosela available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cosela. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Transient protection of normal cells during chemotherapy
Patent 10,085,992
Issued: October 2, 2018
Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
Assignee(s): G1 Therapeutics, Inc.This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034
-
CDK inhibitors
Patent 10,189,849
Issued: January 29, 2019
Inventor(s): Tavares Francis X. & Strum Jay C.
Assignee(s): G1 Therapeutics, Inc.Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓
- October 25, 2031
-
CDK inhibitors
Patent 10,189,850
Issued: January 29, 2019
Inventor(s): Tavares Francis X. & Strum Jay C.
Assignee(s): G1 Therapeutics, Inc.Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓
- October 25, 2031
-
CDK inhibitors
Patent 10,927,120
Issued: February 23, 2021
Inventor(s): Tavares Francis X. & Strum Jay Copeland
Assignee(s): GI Therapeutics, Inc.Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓
- October 25, 2031
-
Transient protection of normal cells during chemotherapy
Patent 10,966,984
Issued: April 6, 2021
Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
Assignee(s): G1 Therapeutics, Inc.This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034
-
Transient protection of normal cells during chemotherapy
Patent 11,040,042
Issued: June 22, 2021
Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
Assignee(s): G1 Therapeutics, Inc.This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034
-
Patent 11,529,352
Patent expiration dates:
- July 23, 2039✓
- July 23, 2039
-
Patent 11,717,523
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034
-
CDK inhibitors
Patent 8,598,186
Issued: December 3, 2013
Inventor(s): Tavares Francis X. & Strum Jay C.
Assignee(s): G1 Therapeutics, Inc.Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓✓
- October 25, 2031
-
CDK inhibitors
Patent 8,598,197
Issued: December 3, 2013
Inventor(s): Tavares Francis X. & Strum Jay C.
Assignee(s): G1 Therapeutics, Inc.Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓✓
- October 25, 2031
-
Transient protection of normal cells during chemotherapy
Patent 9,487,530
Issued: November 8, 2016
Inventor(s): Strum Jay Copeland & Bisi John Emerson & Roberts Patrick Joseph & Tavares Francis Xavier
Assignee(s): G1 Therapeutics, Inc.This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Patent expiration dates:
- March 14, 2034✓
- March 14, 2034✓
- March 14, 2034
-
CDK inhibitors
Patent 9,957,276
Issued: May 1, 2018
Inventor(s): Tavares Francis X. & Strum Jay C.
Assignee(s): GI Therapeutics, Inc.Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Patent expiration dates:
- October 25, 2031✓
- October 25, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 12, 2026 - NEW CHEMICAL ENTITY
More about Cosela (trilaciclib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: other immunostimulants
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.